Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$829.43 USD
+0.59 (0.07%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $829.44 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
REGN 829.43 +0.59(0.07%)
Will REGN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REGN
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
HRMY vs. REGN: Which Stock Is the Better Value Option?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
Other News for REGN
Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer
Regeneron price target lowered by $150 at Oppenheimer, here's why
Regeneron, Sanofi announce EC approval for Dupixent
Regeneron, Sanofi announce EC approval for Dupixent
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)